Most Read Articles
Elaine Soliven, 16 Oct 2018
The use of degludec in insulin-naïve patients with type 2 diabetes (T2D) appears to reduce HbA1c levels with a lower risk of hypoglycaemia, based on real-world data from the CONFIRM* trial presented at EASD 2018.
Audrey Abella, 30 Apr 2018
The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.

Roshini Claire Anthony, 17 Jul 2019

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Pearl Toh, 24 Dec 2018
The anticholinergic agent oxybutynin significantly reduces the intensity and frequency of hot flushes among women in whom hormone replacement therapy was contraindicated such as breast cancer survivors, according to the ACCRU study SC-1603 presented at SABCS 2018.

Certain anti-inflammatory drugs exert beneficial effects in schizophrenia patients

23 Sep 2019

Several anti-inflammatory drugs, including aspirin, oestrogens, minocycline and N-acetylcysteine (NAC), appear to help mitigate symptom severity in patients with schizophrenia, according to a systematic review and meta-analysis.

Researchers searched multiple online databases for randomized controlled trials that explored concomitant use of anti-inflammatory agents in patients with a schizophrenia spectrum disorder (schizophrenia, schizophreniform disorder or schizoaffective disorder). None of the patients had schizotypal and schizoid personality disorder.

The meta-analysis included 56 studies reporting the effect of the following medications on symptom severity: aspirin, bexarotene, celecoxib, davunetide, dextromethorphan, oestrogens, fatty acids, melatonin, minocycline, NAC, pioglitazone, piracetam, pregnenolone, statins, varenicline and withania somnifera extract.

Pooled data revealed that some medications exerted significant beneficial effects on symptom severity, specifically aspirin (n=270; mean weighted effect size [ES], 0.30, 95 percent CI, 0.06–0.54), oestrogens (n=723; ES, 0.78, 0.36–1.19), minocycline (n=946; ES, 0.40, 0.11–0.68) and NAC (n=442; ES, 1.00, 0.60–1.41). In subgroup analysis, these drugs yielded greater positive effects in patients with first-episode psychosis or early-phase schizophrenia.

There were no beneficial effects observed with bexarotene, celecoxib, davunetide, dextromethorphan, fatty acids, pregnenolone, statins and varenicline.

Taken together, the present data support the immune hypothesis in schizophrenia, which suggests a possible treatment for patients in which the underlying pathophysiology is related to a subtle increase in the activation of microglia, according to the researchers. Despite the evidence, further studies are still needed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 16 Oct 2018
The use of degludec in insulin-naïve patients with type 2 diabetes (T2D) appears to reduce HbA1c levels with a lower risk of hypoglycaemia, based on real-world data from the CONFIRM* trial presented at EASD 2018.
Audrey Abella, 30 Apr 2018
The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.

Roshini Claire Anthony, 17 Jul 2019

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Pearl Toh, 24 Dec 2018
The anticholinergic agent oxybutynin significantly reduces the intensity and frequency of hot flushes among women in whom hormone replacement therapy was contraindicated such as breast cancer survivors, according to the ACCRU study SC-1603 presented at SABCS 2018.